25.05.2017 12:49:00

Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Transgenomic, Inc In The District Of Nebraska

NEW YORK, May 25, 2017 /PRNewswire/ -- Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for The District  of Nebraska, case no. 4:17-cv-03021-JMG-FG3, on behalf of unitholders of Transgenomic, Inc, ("Transgenomic " or the "Company") (NASDAQ: TBIO) who held Transgenomic securities and have been harmed by Transgenomic and its board of directors' (the "Board") for alleged violations of Sections 14(a), and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") in connection with the sale of the Company to New Haven Labs Inc. and Precipio Diagnostics, LLC.

Monteverde & Associates PC Logo

Under the terms of the agreement, (i) the outstanding common units of Precipio will be converted into the right to receive approximately 160.6 million shares of common stock of New Precipio ("New Precipio common stock"), which will result in Precipio common unit holders owning approximately 53% of the issued and outstanding shares of New Precipio common stock on a fully diluted basis, taking into account the issuance of shares of convertible preferred stock of New Precipio ("New Precipio preferred stock") in the merger and the private placement (the "fully diluted New Precipio common stock") and (ii) the outstanding preferred units of Precipio will be converted into the right to receive approximately 24.1 million shares of New Precipio preferred stock with an aggregate face amount equal to $3 million (based upon the purchase price of the new preferred stock of New Precipio in the new preferred stock financing), which will result in the Precipio preferred unit holders owning approximately 8% of the fully diluted New Precipio common stock. The complaint alleges that this offer is inadequate and alleges that the Registration Statement in Form S-4 (the "Proxy") provides materially incomplete and misleading information about the Company's financials and the transaction, in violation of Sections 14(a), and 20(a) of the Exchange Act.

If you wish to serve as lead plaintiff, you must move the Court no later than 60 days from today.  Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.  If you wish to discuss this action, or have any questions concerning this notice or your rights or interests, please contact:

Click here for more information: www.monteverdelaw.com/investigations/m-a/ It is free and there is no cost or obligation to you.

Monteverde & Associates PC is a boutique class action securities and consumer litigation law firm committed that has recovered millions of dollars and is committed to protecting shareholders and consumers from corporate wrongdoing.  Monteverde & Associates PC lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct.

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave, Suite 4405
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341

Attorney Advertising. (C) 2017 Monteverde & Associates PC.  Prior results do not guarantee a similar outcome with respect to any future matter. 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/monteverde--associates-pc-files-class-action-lawsuit-on-behalf-of-shareholders-of-transgenomic-inc-in-the-district-of-nebraska-300463836.html

SOURCE Monteverde & Associates PC

Nachrichten zu Transgenomic Incmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Transgenomic Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!